The UK recently released the first set of data for Disclosure UK, which is akin to the Open Payments data in the US (A.K.A, the “Sunshine Act”). Just to recap, pharmaceutical manufacturers made $6.5B in payments to US physicians for general (i.e., non-research related) and research purposes in 2015. Figures released by The Association of the British Pharmaceutical Industry show drug companies disclosed payments to UK doctors and other health professionals totaling £340m (~$450M USD) in 2015. So what’s the difference? Well, compliance with the UK version is not mandatory. Seriously. Financial Times reports that “doctors receiving the largest share of the money are opting out.” Shocker. That said, we were surprised that 70% of doctors participated. Well done, indeed. Cheerio.